In 535 adults with overweight or obesity from the DiOGenes cohort, researchers split insulin resistance into its muscle and liver forms and profiled 1,128 plasma proteins. Muscle insulin resistance tracked 160 proteins dominated by inflammatory pathways, including IL-6 signalling; liver insulin resistance tracked 81 proteins centred on the complement system, with lower IGFBP-1, IGFBP-2, adiponectin and SHBG. Only 12 proteins overlapped. The authors argue this supports tissue-specific rather than one-size-fits-all interventions.
Read source →The inflammaging signature derived from an Italian cohort (InCHIANTI) replicated in another industrialized population (Singapore), but largely vanished in two non-industrialized groups — the Tsimane of the Bolivian Amazon and the Orang Asli of Peninsular Malaysia. In those groups inflammation tracked infection burden rather than age, and showed little association with age-related disease. Suggests inflammaging may be substantially a byproduct of industrialized environments rather than a fixed feature of human aging.
Read source →The design paper for a randomized, double-blind, placebo-controlled trial testing whether clazakizumab, an antibody that blocks interleukin-6, can improve or slow decline in physical, cognitive and vascular function in adults aged 70 and over with low-to-moderate physical function. It is a direct test of the geroscience idea that targeting inflammation itself can extend healthspan. No results yet — this paper describes the rationale and protocol.
Read source →